It has been shown to reduce inflammation by inhibiting the production of TNF-α, a key inflammatory cytokine, leading to improvements in cytokine-mediated systemic inflammatory states and organ function markers in conditions including nonalcoholic steatohepatitis, coronary artery disease or cholestasis-induced renal injury [43,44,45]. This evidence concerns the gene TNF and coronary artery disorder.